ANI Pharmaceuticals Inc. (NASDAQ:ANIP)’s share price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $70.92 and last traded at $70.08, with a volume of 63,292 shares changing hands. The stock had previously closed at $69.58.

A number of equities analysts have recently issued reports on the stock. Guggenheim restated a “buy” rating and issued a $80.00 price objective (up previously from $65.00) on shares of ANI Pharmaceuticals in a research note on Friday, August 5th. Oppenheimer Holdings Inc. increased their price objective on shares of ANI Pharmaceuticals from $65.00 to $71.00 and gave the company an “outperform” rating in a research note on Friday, August 5th. Zacks Investment Research upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $67.00 target price for the company in a research report on Wednesday, July 20th. Citigroup Inc. cut shares of ANI Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $49.00 target price for the company. in a research report on Friday, July 8th. They noted that the move was a valuation call. Finally, Raymond James Financial Inc. initiated coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, June 22nd. They set a “strong-buy” rating and a $68.00 target price for the company. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $64.00.

The company has a 50 day moving average price of $60.53 and a 200 day moving average price of $46.58. The company has a market cap of $797.81 million and a PE ratio of 81.42.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Thursday, August 4th. The specialty pharmaceutical company reported $1.11 EPS for the quarter, topping the Zacks’ consensus estimate of $0.77 by $0.34. During the same period last year, the firm earned $0.55 earnings per share. The company had revenue of $31.30 million for the quarter, compared to the consensus estimate of $27.63 million. The company’s revenue for the quarter was up 60.5% compared to the same quarter last year. On average, equities research analysts forecast that ANI Pharmaceuticals Inc. will post $4.12 earnings per share for the current year.

In other ANI Pharmaceuticals news, VP Robert W. Schrepfer sold 12,500 shares of ANI Pharmaceuticals stock in a transaction on Monday, August 8th. The shares were sold at an average price of $67.06, for a total transaction of $838,250.00. Following the completion of the transaction, the vice president now directly owns 17,362 shares of the company’s stock, valued at $1,164,295.72. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

A hedge fund recently raised its stake in ANI Pharmaceuticals stock. Mutual of America Capital Management LLC increased its position in ANI Pharmaceuticals Inc. (NASDAQ:ANIP) by 0.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 30,178 shares of the specialty pharmaceutical company’s stock after buying an additional 178 shares during the period. Mutual of America Capital Management LLC owned about 0.26% of ANI Pharmaceuticals worth $1,362,000 at the end of the most recent reporting period.

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.